Browse Category

Investing News 8 October 2025 - 9 October 2025

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

What Is the FTSE 100 Index? The FTSE 100 (Financial Times Stock Exchange 100) is the flagship stock index of the London Stock Exchange, tracking the 100 largest companies by market capitalization listed in the UK. Often called the “Footsie,” it serves as a barometer of British large-cap equities. The index is market-cap weighted, meaning each company’s influence on the index is proportional to its market value (adjusted for free-float shares) theguardian.com. In practical terms, bigger companies like Shell or HSBC move the FTSE 100 far more than smaller constituents. The FTSE 100 is maintained by FTSE Russell (part of London Stock Exchange Group) and
9 October 2025
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) stocktitan.net; FDA Breakthroughdesignation in 2025 stocktitan.net; BLA filing planned for 2025. Sold to US WorldMeds (2025) adaptimmune.com Uzatresegene (uza-cel, next-gen TCR) Solid tumors (MAGE-A4 TCR, partnered with Galapagos) Preclinical/IND-enabling stage; partnership deal $665M signed 2024 fiercebiotech.com. Sold to US WorldMeds (2025) adaptimmune.com PRAME-targeted TCR Multiple cancers (PRAME antigen) Preclinical (IND-enabling on hold to cut costs) biospace.com. Retained by Adaptimmune adaptimmune.com CD70-targeted TCR Hematologic malignancies
8 October 2025
Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Below, we dive deeper into each of these areas – from Snowflake’s business model and financials to the latest news, analyst insights, competitive dynamics, and what to expect going forward. Company Overview and Business Model Snowflake Inc. is a cloud data platform provider, offering data warehousing as a service alongside a suite of data analytics and sharing capabilities. Unlike traditional databases tied to a single cloud or on-premises, Snowflake’s platform is cloud-agnostic – it runs across Amazon AWS, Microsoft Azure, and Google Cloud, allowing customers to unify their data in one system regardless of cloud provider markets.chroniclejournal.com. This flexibility has been a major selling
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior session stockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31 stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remains stockinvest.us.
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64 indmoney.com investing.com. Reuters reported that the last trade was $371.46, up 2.15 % from the previous day reuters.com. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the severity of the 2025 sell‑off. The stock’s average daily trading volume is about 5.9 million shares, and its beta of 0.47 indicates less volatility than the S&P 500 reuters.com marketbeat.com. Year‑to‑date performance remains negative (‑28 % to ‑37 % depending on the reference period),
8 October 2025
Reddit’s Stock Explodes! 78% Revenue Surge, Google AI Deal Talks & 70% Rally 🔥

Reddit’s Rollercoaster: How Booming Ads, AI Deals and Political Scrutiny Could Shock RDDT Investors

Key Facts (as of 8 Oct 2025) Item Detail Sources Current stock price Reddit’s Class A shares traded around $199.54 at 11:58 AM EDT on 8 Oct 2025 with an intraday high of $206.22 and low of $195.01; the official investor‑relations site notes a 52‑week high of $282.95 and low of $69.30 investor.redditinc.com. Reddit investor relations Analyst consensus Across 25‑28 analysts the consensus rating is “moderate/buy”. Average price targets range from $200–$223, with highs around $300 (JMP Securities, Oppenheimer) and lows near $75 marketbeat.com benzinga.com. MarketBeat, Stockanalysis, Benzinga Q2 2025 results Reddit delivered its first profitable quarter: revenue rose 78 % to $500 M and advertising revenue jumped 84 % to
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Introduction: A New Kind of Biotech Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labs directorstalkinterviews.com nasdaq.com. Its mission – “to decode biology to radically improve lives” – has attracted major industry partners and bold investors. But as an early-stage biotech with no approved drugs, Recursion’s stock can be a rollercoaster ride, swayed by scientific milestones and market sentiment alike. In early October 2025, Recursion’s stock made headlines after a
Webull’s Wild Ride: Inside BULL Stock’s 500% Surge, 85% Crash & What’s Next for the Trading App Giant

Webull’s Wild Ride: Inside BULL Stock’s 500% Surge, 85% Crash & What’s Next for the Trading App Giant

Company Overview Webull is a digital investment platform that offers commission-free trading of stocks, ETFs, options, cryptocurrencies and more via a popular mobile app and web interface cmcmarkets.com. Often likened to Robinhood, Webull makes money primarily through payment for order flow and premium add-on services cmcmarkets.com. The platform launched in 2018 and quickly gained traction among tech-savvy retail investors with its sleek design and zero-commission model. Webull now serves customers in North America, Europe, Asia, Africa, and beyond, operating in 14 markets through its licensed broker-dealer entities stockanalysis.com. Originally founded in 2016 as part of a Chinese fintech venture, Webull was backed
SoundHound AI Stock Soars 240% – Could This Voice Tech Disruptor Make You a Millionaire?

SoundHound AI Stock Soars 240% – Could This Voice Tech Disruptor Make You a Millionaire?

SOUN Stock Surges on AI Hype and Big News SoundHound AI’s stock has been on a tear in recent months, riding the wave of excitement surrounding artificial intelligence. The company’s share price has climbed roughly 240% over the past year (and more than doubled in the last six months) ts2.tech. Just in the past week, SOUN jumped about 15%, climbing from the mid-$15s to around $18 per share, amid a broader AI stock rally. One catalyst was Advanced Micro Devices (AMD) announcing a blockbuster partnership with OpenAI: the ChatGPT creator will use up to 6 gigawatts of AMD chips to
Wall Street’s $2 Billion Bet on the Future: NYSE Owner Goes All-In on Polymarket Prediction Markets

Wall Street’s $2 Billion Bet on the Future: NYSE Owner Goes All-In on Polymarket Prediction Markets

ICE’s $2B Vote of Confidence in Polymarket Wall Street’s biggest exchange operator is making a bold bet that betting on real-world events is the next big financial frontier. Intercontinental Exchange Inc. (ICE) – the owner of the NYSE – confirmed it will invest $2 billion in Polymarket, a deal that values the crypto-powered betting platform at roughly $8 billion pre-money (around $10B post-investment) reuters.com reuters.com. This is a landmark endorsement of prediction markets by a mainstream financial giant. The deal, first reported by The Wall Street Journal and Bloomberg, could be officially announced any day ts2.tech. Why it matters: ICE’s
8 October 2025
Silver Near $50 – Is a New Record Imminent? Inside 2025’s Soaring Silver Surge

Silver Near $50 – Is a New Record Imminent? Inside 2025’s Soaring Silver Surge

Silver Soars to 14-Year Highs, Closing in on Record Levels Silver’s price has exploded upward in 2025, putting the vaunted $50 per ounce milestone within sight. As of October 8, 2025, spot silver trades around $48.8/oz investing.com – territory not seen since 2011. Just days earlier it touched $47.8, the loftiest price in over 14 years ts2.tech. This puts silver only a few percentage points below its all-time nominal high of ~$49.50 (set in April 2011) ts2.tech. The metal’s ascent this year has been stunning: silver is up roughly 60–65% year-to-date investing.com, after starting 2025 in the low $30s. By
Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Is TLRY’s Rally Sustainable?

Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Is TLRY’s Rally Sustainable?

Tilray’s Stock Price Soars on Reform Speculation Tilray’s stock has been on a tear in recent months, staging a stunning turnaround from penny-stock levels. The share price has quadrupled since early July – rising from well under $0.5 to around $1.7 by early October nasdaq.com. Year-to-date, TLRY is up ~22% (as of Oct. 8) after being down over 20% mid-year talkmarkets.com hi-plainscoop.com. This rebound has rescued Tilray from the brink of a Nasdaq delisting – the company had even sought a compliance extension when its shares languished below $1 in the summer hi-plainscoop.com. The rally hit overdrive in late September 2025. On September 29, Tilray skyrocketed 42%
1 52 53 54 55 56 65
Go toTop